Oncology ASCO 2024 – Thanos Zomas Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.